Published research on Cagrilintide: record counts, recent publications, reviews and registered studies, pulled from PubMed and ClinicalTrials.gov. Part of metabolic research.
Ask TinaTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Registered studies by status: 11 recruiting, 7 active not recruiting, 24 completed.
Number of PubMed records mentioning Cagrilintide, 2016 to 2026 (2026 is year to date).
Most recently started of 44 ClinicalTrials.gov entries.
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251 · Recruiting · Phase 3 · started 2026-09-16A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 · Withdrawn · Phase 2 · started 2026-08-27A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504 · Recruiting · Phase 3 · started 2026-08-04A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · Recruiting · Phase 3 · started 2026-08-04A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 · Withdrawn · Phase 3 · started 2026-06-22Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 · Recruiting · Phase 1 · started 2026-05-29A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · Recruiting · Phase 3 · started 2026-05-21A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 · Completed · Phase 1 · started 2026-05-20A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or ObesityNCT07597018 · Recruiting · Phase 1 · started 2026-05-18A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or ObesityNCT07557953 · Recruiting · Phase 1 · started 2026-04-30Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)NCT07527195 · Recruiting · Phase 1 · started 2026-04-10A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or ObeseNCT07411560 · Recruiting · Phase 1 · started 2026-02-09Primary data for your own interpretation: published studies and regulator documents. No publisher opinion pieces.
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet · 2025 Nov 6 · Muskiet MHA et al. · PubMedGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract · 2026 Oct · Singhani V et al. · PubMedBeyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs.Pharmacol Res · 2026 Aug 12 · Fischer SL et al. · PubMedEfficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.Diabetes Metab Syndr Obes · 2026 Sep 15 · Shao C et al. · PubMedRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes Metab Syndr Obes · 2026 Sep 2 · Puspitasari IM et al. · PubMedEfficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.Ann Intern Med · 2026 Sep 1 · Moiz A et al. · PubMedWeight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring) · 2025 Nov 4 · Li C et al. · PubMedComparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.BMJ Med · 2026 Aug 27 · Chen D et al. · PubMedBenefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.Ann Intern Med · 2026 Jun 16 · Damen JAA et al. · PubMedEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.Lancet Diabetes Endocrinol · 2026 Jun 7 · Aroda VR et al. · PubMedAsk Tina for links to further coverageTina is an AI research guide who has read the published research collected here and shares it as objectively as she can, for free. She's not a doctor and doesn't give medical advice.
Third-party links, listed for reference. Educational information only, not medical advice. Hypnotic Dose does not endorse any product.